Next Article in Journal
Non-Coding RNAs and Splicing Activity in Testicular Germ Cell Tumors
Previous Article in Journal
The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections
 
 
Article

In-Hospital Mortality of COVID-19 Patients Treated with High-Flow Nasal Oxygen: Evaluation of Biomarkers and Development of the Novel Risk Score Model CROW-65

1
Department of Anesthesiology and Intensive Medicine, University Hospital of Split, 21000 Split, Croatia
2
Department of Infectious Diseases, University Hospital of Split, 21000 Split, Croatia
3
Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia
4
Department of Cardiology, University Hospital of Split, 21000 Split, Croatia
*
Author to whom correspondence should be addressed.
Academic Editors: Daniele Focosi and Christian Lehmann
Life 2021, 11(8), 735; https://doi.org/10.3390/life11080735
Received: 27 June 2021 / Revised: 20 July 2021 / Accepted: 21 July 2021 / Published: 23 July 2021
To replace mechanical ventilation (MV), which represents the cornerstone therapy in severe COVID-19 cases, high-flow nasal oxygen (HFNO) therapy has recently emerged as a less-invasive therapeutic possibility for those patients. Respecting the risk of MV delay as a result of HFNO use, we aimed to evaluate which parameters could determine the risk of in-hospital mortality in HFNO-treated COVID-19 patients. This single-center cohort study included 102 COVID-19-positive patients treated with HFNO. Standard therapeutic methods and up-to-date protocols were used. Patients who underwent a fatal event (41.2%) were significantly older, mostly male patients, and had higher comorbidity burdens measured by CCI. In a univariate analysis, older age, shorter HFNO duration, ventilator initiation, higher CCI and lower ROX index all emerged as significant predictors of adverse events (p < 0.05). Variables were dichotomized and included in the multivariate analysis to define their relative weights in the computed risk score model. Based on this, a risk score model for the prediction of in-hospital mortality in COVID-19 patients treated with HFNO consisting of four variables was defined: CCI > 4, ROX index ≤ 4.11, LDH-to-WBC ratio, age > 65 years (CROW-65). The main purpose of CROW-65 is to address whether HFNO should be initiated in the subgroup of patients with a high risk of in-hospital mortality. View Full-Text
Keywords: COVID-19; HFNO; in-hospital outcomes; mechanical ventilation; risk scores COVID-19; HFNO; in-hospital outcomes; mechanical ventilation; risk scores
Show Figures

Figure 1

MDPI and ACS Style

Kljakovic Gaspic, T.; Pavicic Ivelja, M.; Kumric, M.; Matetic, A.; Delic, N.; Vrkic, I.; Bozic, J. In-Hospital Mortality of COVID-19 Patients Treated with High-Flow Nasal Oxygen: Evaluation of Biomarkers and Development of the Novel Risk Score Model CROW-65. Life 2021, 11, 735. https://doi.org/10.3390/life11080735

AMA Style

Kljakovic Gaspic T, Pavicic Ivelja M, Kumric M, Matetic A, Delic N, Vrkic I, Bozic J. In-Hospital Mortality of COVID-19 Patients Treated with High-Flow Nasal Oxygen: Evaluation of Biomarkers and Development of the Novel Risk Score Model CROW-65. Life. 2021; 11(8):735. https://doi.org/10.3390/life11080735

Chicago/Turabian Style

Kljakovic Gaspic, Toni, Mirela Pavicic Ivelja, Marko Kumric, Andrija Matetic, Nikola Delic, Ivana Vrkic, and Josko Bozic. 2021. "In-Hospital Mortality of COVID-19 Patients Treated with High-Flow Nasal Oxygen: Evaluation of Biomarkers and Development of the Novel Risk Score Model CROW-65" Life 11, no. 8: 735. https://doi.org/10.3390/life11080735

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop